Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766463 | 0.77 | TERT (0.34) | DRD2DRD4TERT | |
| SCHEMBL6319520 | 0.75 | PARP1 (0.41) | PARP1DRD2DRD4ALDH1A1MAPT | |
| SCHEMBL6319381 | 0.64 | KDR (0.40) | SIGMAR1 | |
| SCHEMBL5842762 | 0.62 | TERT (0.52) | DRD2TERTSIGMAR1 | |
| SCHEMBL2559154 | 0.62 | KDR (0.47) | ALDH1A1MAPTKMT2AMAPK1 | |
| SCHEMBL26092163 | 0.61 | ALDH1A1 (0.58) | DRD2DRD4ALDH1A1POLBKMT2A | |
| SCHEMBL30379612 | 0.61 | ALDH1A1 (0.58) | DRD2DRD4ALDH1A1POLBKMT2A | |
| SCHEMBL26088422 | 0.59 | ALDH1A1 (0.46) | DRD2DRD4ALDH1A1MAPTPOLB | |
| SCHEMBL30910089 | 0.59 | ALDH1A1 (0.46) | DRD2DRD4ALDH1A1MAPTPOLB | |
| SCHEMBL949323 | 0.59 | ALDH1A1 (0.61) | ALDH1A1MAPTPOLBKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | PARP1 1368/4885DRD2 3857/4885DRD4 3278/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | PARP1 1368/4885DRD2 3857/4885DRD4 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.